USPTO serial 79398079
HARNESS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 19, 2025
- Examiner
- KEENAN, CAYLA FAY
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with HARNESS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
GB
GB
GB
GB
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Rebecca Liebowitz
Rebecca Liebowitz Venable LLPP.O. Box 34385Washington, DC 20043-9998United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for scientific purposes; chemicals for use in scientific research; chemicals, enzymes, biological preparations in the nature of DNA and RNA for scientific research use; chemicals for scientific research use in the preparation and creation of DNA and RNA; enzymes for scientific research purposes for use in the preparation and creation of DNA and RNA; molecular biology research tools in the nature of biological, chemical and biochemical reagents for research use | ACTIVE | — |
| 005 | Pharmaceutical preparations for the treatment and prevention of ophthalmological conditions, hearing loss, hematologic diseases, immune response disorders, neurological disorders, psychiatric disorders, respiratory diseases, fibrosis, hepatic diseases, renal diseases, diseases of the pancreas, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; medical and veterinary preparations for therapeutic purposes for the treatment and prevention of ophthalmological conditions, hearing loss, hematologic diseases, immune response disorders, neurological disorders, psychiatric disorders, respiratory diseases, fibrosis, hepatic diseases, renal diseases, diseases of the pancreas, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; biological, chemical and biochemical reagents for medical use; DNA, RNA, oligonucleotides, polynucleotides for medical use; gene editing enzymes for medical use; medical preparations containing therapeutic DNA and RNA, namely, nucleic and sequences for medical purposes; all of the foregoing excluding dietary and nutritional supplements | ACTIVE | — |
| 042 | Scientific and technological services and research and design relating thereto namely scientific research services in the field of genomics; medical research services including the manipulation of biological reagents to be used for medical or therapeutic purposes; chemical and biological analysis and research services; scientific research into DNA and RNA; research and development into the creation of DNA and RNA; research and development services in the manufacture of synthetic DNA, RNA, genes and oligonucleotides for others; research, development, testing and analysis for scientific research purposes in the field of genomics, DNA and RNA sequencing, gene synthesis, gene identification, gene cloning, gene expression, gene mapping; scientific research in the field of molecular biology, next generation sequencing, high-throughput sequencing and bioinformatics; gene-editing services for scientific research purposes; DNA and RNA modelling services, namely, genetic mapping for scientific research purposes; gene engineering services; research and development services in the creation of genome libraries and collections of biologicals including chemicals and compounds; research and development services in creating libraries and collections of normal and mutated genes; scientific services research relating to the discovery, preclinical and clinical development of therapeutic products, namely, therapeutic DNA and RNA; consultancy and advisory services relating to the aforesaid services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Harness Therapeutics Limited
- Other trademarks owned by Harness Therapeutics Limited
- Other trademarks owned by Harness Therapeutics Limited
- Other trademarks owned by Harness Therapeutics Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named HARNESS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 19, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 2, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 2, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Dec 5, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Nov 19, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 19, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 19, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Aug 19, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 19, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 3, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 3, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 28, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 6, 2025 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Apr 15, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 2, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 2, 2025 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Apr 2, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 2, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 2, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 2, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Mar 21, 2025 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Mar 19, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 14, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 14, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 14, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 30, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 30, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 7, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 16, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 16, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 13, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 12, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 9, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 24, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 24, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 20, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |